Extensive-stage small-cell lung cancer

Seminars in Surgical Oncology

Volumn 21, Issue 3, 2003, Pages 164-175

  Spira, Alexander ^a   Ettinger, David S ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cisplatin; Etopiside; Small cell lung cancer; Topotecan

Indexed keywords

ALPHA TOCOPHEROL; ALTRETAMINE; ANTIBIOTIC AGENT; CARBOPLATIN; CISPLATIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GYRASE INHIBITOR; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; TENIPOSIDE; TOPOTECAN; VINCRISTINE; VINDESINE;

ADVANCED CANCER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DIARRHEA; DISEASE SEVERITY; DRUG FATALITY; ELDERLY CARE; FEBRILE NEUTROPENIA; HUMAN; LONG TERM CARE; LUNG SMALL CELL CANCER; MAINTENANCE DRUG DOSE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT PLANNING; VOMITING;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SMALL CELL; CISPLATIN; CRANIAL IRRADIATION; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS;

EID: 0141928688     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/ssu.10034     Document Type: Review

References (79)

1. Page NC, Read WL, Tierney RM: The epidemiology of small cell lung cancer [Abstract]. Proc Am Soc Clin Oncol 2002;21:305a.
2. Zelen M: Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 1973;4:31-42.
3. Stahel RA, Ginsberg R, Havemann K: Staging and prognostic features in small cell lung cancer; a consensus report. Lung Cancer 1989;59:119-126.
4. Micke P, Faldum A, Metz T, et al: Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer-what limits limited disease? Lung Cancer 2002;37:271-276.
5. Light RW, Hamm H: Malignant pleural effusion: would the real cause please stand up? Eur Respir J 1997;10:1701-1702.
6. Jackson DV Jr, Case LD, Zekan PJ, et al: Improvement of long-term survival in extensive small-cell lung cancer. J Clin Oncol 1988;6:1161-1169.
7. Evans WK, Osoba D, Feld R, et al: Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer. J Clin Oncol 1985;3:65-71.
8. Evans WK, Feld R, Osoba D, et al: VP-16 alone and in combination with cisplatin in previously treated patients with small cell lung cancer. Cancer 1984;53:1461-1466.
9. Fukuoka M, Furuse K, Saijo N, et al: Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991;83:855-861.
10. Roth BJ, Johnson DH, Einhorn LH, et al: Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992;10:282-291.
11. Pujol JL, Daures JP, Riviere A, et al: Etoposide plus cisplatin with or without the combination of 4′-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. J Natl Cancer Inst 2001;93:300-308.
12. Pace A, Savarese A, Picardo M, et al: Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol 2003;21:927-931.
13. Chute JP, Chen T, Feigal E, et al: Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999;17:1794-1801.
14. Mascaux C, Paesmans M, Berghmans T, et al: A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 2000;30:23-36.
15. Pujol JL, Carestia L, Daures JP: Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 2000;83:8-15.
16. Noda K, Nishiwaki Y, Kawahara M, et al: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91.
17. Kosmidis PA, Samantas E, Fountzilas G, et al: Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials. Semin Oncol 1994;21(3 Suppl 6):23-30.
18. Lassen U, Kristjansen PE, Osterlind K, et al: Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomized trial with 5 years follow up. Ann Oncol 1996;7:365-371.
19. Brahmer JR, Ettinger DS: Carboplatin in the treatment of small cell lung cancer. Oncologist 1998;3:143-154.
20. Joss RA, Bacchi M, Hurny C, et al: Early versus late alternating chemotherapy in small-cell lung cancer. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1995;6:157-166.
21. Feld R, Evans WK, Deboer G, et al: Combined modality induction therapy without maintenance chemotherapy for small cell carcinoma of the lung. J Clin Oncol 1984;2:294-304.
22. Maurer LH, Tulloh M, Weiss RB, et al: A randomized combined modality trial in small cell carcinoma of the lung: comparison of combination chemotherapy-radiation therapy versus cyclophosphamide-radiation therapy effects of maintenance chemotherapy and prophylactic whole brain irradiation. Cancer 1980;45:30-39.
23. Cullen M, Morgan D, Gregory W, et al: Maintenance chemotherapy for anaplastic small cell carcinoma of the bronchus: a randomised, controlled trial. Cancer Chemother Pharmacol 1986;17:157-160.
24. Hanna NH, Sandier AB, Loehrer Sr PJ, et al: Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study. Ann Oncol 2002;13:95-102.
25. Ettinger DS, Finkelstein DM, Abeloff MD, et al: A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group. J Clin Oncol 1990;8:230-240.
26. Einhorn LH, Crawford J, Birch R, et al: Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer. J Clin Oncol 1988;6:451-456.
27. Spiro SG, Souhami RL, Geddes DM, et al: Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer 1989;59:578-583.
28. Giaccone G, Dalesio O, McVie GJ, et al: Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1993;11:1230-1240.
29. Byrne MJ, van Hazel G, Trotter J, et al: Maintenance chemotherapy in limited small cell lung cancer: a randomised controlled clinical trial. Br J Cancer 1989;60:413-418.
30. Sculier JP, Berghmans T, Castaigne C, et al: Maintenance chemotherapy for small cell lung cancer: a critical review of the literature. Lung Cancer 1998;19:141-151.
31. Schiller JH, Adak S, Cella D, et al: Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593-a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:2114-2122.
32. Sculier JP, Joss RA, Schefer H, et al: Should maintenance chemotherapy be used to treat small cell lung cancer? Eur J Cancer 1998;34:1148-1155.
33. Goldie JH, Coldman AJ: A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63:1727-1733.
34. Urban T, Baleyte T, Chastang CL, et al: Standard combination versus alternating chemotherapy in small cell lung cancer: a randomised clinical trial including 394 patients. "Petites Cellules" Group. Lung Cancer 1999;25:105-113.
35. Wolf M, Pritsch M, Drings P, et al: Cyclic-alternating versus response-oriented chemotherapy in small-cell lung cancer: a German multicenter randomized trial of 321 patients. J Clin Oncol 1991;9:614-624.
36. Hryniuk W, Bush H: The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984;2:1281-1288.
37. Klasa RJ, Murray N, Coldman AJ: Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol 1991;9:499-508.
38. De Vathaire F, Arriagada R, de Thé H: Dose intensity of initial chemotherapy may have an impact on survival in limited small cell lung cancer. Lung Cancer 1993;8:301.
39. Ihde DC, Mulshine JL, Kramer BS, et al: Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 1994;12:2022-2034.
40. Johnson DH, Wolff SN, Hainsworth JD, et al: Extensive-stage small-cell bronchogenic carcinoma: intensive induction chemotherapy with high-dose cyclophosphamide plus high-dose etoposide. J Clin Oncol 1985;3:170-175.
41. Arriagada R, Le Chevalier T, Pignon JP, et al: Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 1993;329:1848-1852.
42. Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164-170.
43. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup trial C9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol 2003;21:1431-1439.
44. Berghmans T, Paesmans M, Lafitte JJ, et al: Role of granulocyte and granulocyte-macrophage colony-stimulating factors in the treatment of small-cell lung cancer: a systematic review of the literature with methodological assessment and meta-analysis. Lung Cancer 2002;37:115-123.
45. Nichols CR, Fox EP, Roth BJ, et al: Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor. J Clin Oncol 1994;12:1245-1250.
46. Chouaid C, Bassinet L, Fuhrman C, et al: Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model. J Clin Oncol 1998;16:2700-2707.
47. Norton L, Simon R: The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986;70:163-169.
48. Humblet Y, Symann M, Bosly A, et al: Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. J Clin Oncol 1987;5:1864-1873.
49. Pasini F, Durante E, De Manzoni D, et al: High-dose chemotherapy in small-cell lung cancer. Anticancer Res 2002;22:3465-3472.
50. Thatcher N, Lee SM, Woll PJ, et al: Dose intensity in small cell lung cancer. Semin Oncol 1998;25(2 Suppl 4):12-18.
51. Fetscher S, Brugger W, Engelhardt R, Kanz L, Hasse J, Frommhold H, Lange W, Mertelsmann R: Stan. Ann Oncol 1999;10:561-567.
52. Woll PJ, Lomax L, Hodgetts J: Tolerability of dose-intensive, modified ICE chemotherapy for SCLC with filgrastim and reinfusion of hematopoietic progenitors in whole blood. Lung Cancer 1997;18:30a.
53. Rizzo JD, Elias AD, Stiff PJ, et al: Autologous stem cell transplantation for small cell lung cancer. Biol Blood Marrow Transpl 2002;8:273-280.
54. Loehrer Sr PJ, Ansari R, Gonin R, et al: Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. J Clin Oncol 1995;13:2594-2599.
55. Mavroudis D, Papadakis E, Veslemes M, et al: A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann Oncol 2001;12:463-470.
56. Hainsworth JD, Morrissey LH, Scullin DC Jr, et al: Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer 2002;94:2426-2433.
57. Simon GR, Wagner H: Small cell lung cancer. Chest 2003; (123Suppl 1):259S-271S.
58. Giaccone G, Donadio M, Bonardi G, et al: Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy. J Clin Oncol 1988;6:1264-1270.
59. Giaccone G, Ferrati P, Donadio M, et al: Reinduction chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol 1987;23:1697-1699.
60. Ardizzoni A, Hansen H, Dombernowsky P, et al: Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997;15:2090-2096.
61. von Pawel J, Schiller JH, Shepherd FA, et al: Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-667.
62. Ardizzoni A, Manegold C, Debruyne C, et al: Giuseppe glaccone European organization for research and treatment of cancer (EORTC) lung cancer group. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. Clin Cancer Res 2003;9(1):143-150.
63. Einhorn LH, Pennington K, McClean J: Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study. Semin Oncol 1990;17(1 Suppl 2):32-35.
64. Johnson DH, Greco FA, Strupp J, et al: Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. J Clin Oncol 1990;8:1613-1617.
65. a. Hoang T, Kim KM, Jaslowski A, Koch P, et al: Phase II study of gencitabine as second-line therapy in patients with small cell lung cancer [Abstract]. Proc Am Soc Clin Oncol 2002;21:604.
66. Sculier JP, Lafitte JJ, Lecomte J, et al: A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer. Ann Oncol 2002;13:1454-1459.
67. Dajczman E, Fu LY, Small D, et al: Treatment of small cell lung carcinoma in the elderly. Cancer 1996;77:2032-2038.
68. Quon H, Shepherd FA, Payne DG, et al: The influence of age on the delivery, tolerance, and efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer. Int J Radiat Oncol Biol Phys 1999;43:39-45.
69. Girling DJ: Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party. Lancet 1996;348(9027):563-566.
70. Souhami RL, Spiro SG, Rudd RM, et al: Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst 1997;89:577-580.
71. Auperin A, Arriagada R, Pignon JP, et al: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999;341:476-484.
72. Hanna NH, Einhorn LH: Small cell lung cancer: state of the art. Clin Lung Cancer 2002;4:87-94.
73. Johnson BE. NCCN: small cell lung cancer. Cancer Control 2001;8(6 Suppl 2):32-43.
74. Kalemkerian GP, Jiroutek M, Ettinger DS, et al: A phase II study of all-trans-retinoic acid plus cisplatin and etoposide in patients with extensive stage small cell lung carcinoma: an Eastern Cooperative Oncology Group Study. Cancer 1998;83:1102-1108.
75. Lee SM, James LE, Mohamed-Ali V, et al: Tolerability of dose-intensive, modified ICE chemotherapy for SCLC with filgrastim and reinfusion of hematopoietic progenitors in whole blood. Proc Am Soc Clin Oncol 2002;1251.
76. Johnson BE, Fisher B, Fisher T, et al: Phase II study of STI571 (Gleevec) for patients with small cell lung cancer. Proc Am Soc Clin Oncol 2002;1171.
77. Grant SC, Kris MG, Houghton AN, Chapman PB: Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin. Clin Cancer Res 1999;5:1319-1323.
78. Ettinger DS, Finkelstein DM, Abeloff MD, et al: Justification for evaluating new anticancer drugs in selected untreated patients with extensive-stage small-cell lung cancer: an Eastern Cooperative Oncology Group randomized study. J Natl Cancer Inst 1992;84:1077-1084.
79. Evans WK, Feld R, Murray N, et al: Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada. Ann Intern Med 1987;107:451-458.